A Driven and Passionate Team

We are a team dedicated to defeating degeneration. We are passionate about solving problems with rigorous science and translational medicine. We have joined together to discover and develop therapies that will change the lives of patients suffering from neurodegenerative disease.

Join Us

Senior Leadership

We have assembled a team with deep scientific, clinical, business and leadership experience and expertise in biotechnology, and specifically in neurodegenerative diseases.
Ryan Watts

Chief Executive Officer

Alex Schuth

Chief Operating and Financial Officer

Carole Ho

Chief Medical Officer

Dana Andersen

Chief Technical and Manufacturing Officer

Cindy Dunkle

Chief People Officer

Joe Lewcock

Chief Scientific Officer

Chris Walsh

Associate General Counsel

Katie Peng

Chief Commercial Officer

Dolo Diaz

Senior Vice President, Development Sciences

Wei Dong

Vice President, Drug Safety

Peter Chin

SVP Late Clinical Development & Medical Affairs

Matt Troyer

Senior Vice President, Early Clinical

Cynthia Wong

Senior Vice President, Portfolio and Program Management

Erica Kratz

Vice President, Regulatory

Tyler Nielsen

Vice President, Corporate Finance

Anantha Sudhakar

Vice President, CMC Small Molecule

Tony Estrada

Senior Vice President, Discovery Sciences

Darren Hart

Vice President, Development Operations

Kimberly Scearce-Levie

Vice President, Translational Sciences

Laura Hansen

Vice President, Investor Relations

Leah Frautschy

Vice President, Clinical Manufacturing

Fabian Model

Vice President, Biometrics

Kirk Henne

Vice President, Translational Pharmacology and Bioanalysis

Board of Directors

Success is accelerated by experience, collaboration and leadership. Denali’s Board of Directors combines expertise across industry, academia, drug development and the investment community, unified by the mission to improve the lives of patients.
Douglas Cole

Managing Partner of Flagship Pioneering

Jennifer Cook

Former CEO, Grail

Jay Flatley

Former CEO, Chairman of Illumina, Inc.

Erik Harris

CCO and EVP, Ultragenyx

Peter Klein

Former CFO, Microsoft

Steve Krognes

Former CFO, Denali Therapeutics

Robert Nelsen

Managing Director and Co-Founder of Arch Venture Partners

Vicki Sato

Chair of Denali Board

David Schenkein

General Partner, GV

Marc Tessier-Lavigne

President, Stanford University

Nancy A. Thornberry

Chair R&D, Former CEO, Kallyope

Ryan Watts

Chief Executive Officer

Scientific Advisory Board

Denali's Scientific Advisory Board brings experience from both industry and academia to provide insight around biological pathways, therapeutic strategies, and biomarker development.